Eli Lilly (LLY) Acquires Centessa to Advance Sleep Disorder Drugs

Eli Lilly and Company (NYSE:LLY) announced the completion of its acquisition of Centessa Pharmaceuticals on June 24, 2026. The deal aims to accelerate the development of orexin receptor 2 agonists, a novel class of medicines designed to treat narcolepsy and other sleep-wake disorders by targeting the brain's orexin system.

Deal Details

• Acquirer: Eli Lilly (LLY)
• Target: Centessa Pharmaceuticals
• Closing Date: June 24, 2026
• Purpose: Develop orexin receptor 2 agonists

Rationale

Eli Lilly seeks to strengthen its pipeline in sleep disorder treatments. Orexin receptor 2 agonists are an innovative class that promotes wakefulness by activating orexin receptors in the brain, potentially offering new options for patients with narcolepsy and related conditions.

Regulatory Hurdles

No regulatory challenges have been reported yet. The deal may face antitrust review given Lilly's size, but no obstacles have been announced.

Impact on Stock

No immediate stock reaction has been reported for Eli Lilly (LLY). Investors may view the acquisition positively if the new therapies prove effective in clinical trials. LLY is considered one of the best stocks for beginners, according to prior sources.